A suited approach to rare disease trialsOPIS Accelerated approval for orphan drugs and the possibility to have market authorisationafter a successful Phase II trial have made research in rare diseases more attractive to sponsors.However, … more ➔
4SC AG, EU patent, José Pfizer, unified patent vs bundle patent, UPC system “We have mixed feelings…”...Unitary Patent:?Ingve Stjerna, plaintiff before the Federal Constitutional Court, argues that the UPC system does not deliver on its promise to make European patents cheaper and more affordable to Small … more ➔
Align Biopharma, HCP Streamlining Digital Engagement with HCPsToday, there are greater expectations among healthcare providers for engagement with life sciences companies to be digital. For life sciences companies, there is significant potential to leverage digital … more ➔
Talents: HR FlashThe European Biotech market is extremely dynamic, acknowledged as being number two in the world of market rankings. This is a cause for celebration! more ➔
Polpharma: Making biologics economicAfter having set up a R&D hub for the biomanufacturing of clinical trial supplies in Gdansk, Polpharma is expanding its European footprint with a €100m investment in Warsaw. Several take-overs … more ➔
IP: Brexit and patentsOn 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions … more ➔
Biosimilars labellingEuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency for the label. more ➔
Benefits and challenges in pharma innovati...We are living in a world of cutting-edge science, which holds the potential to transform the landscape for patients living with common and rare diseases within the next five years. This is of particular … more ➔
Crowdfunding: Fuelling EU biotechSpanish Capital Cell was one of the first equity crowdfunding platforms that specialised in life sciences and biotech projects in Europe. In March, the group raised more than €1m through funding through … more ➔
IP Flash: Bayer sees advantages for enforc...Bayer has always been extremely supportive of the new Unitary Patent System (UPS) and has been one of the driving forces behind it within the German industry. However, the company will not be putting … more ➔
